Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
  • G01N33/54366—Apparatus specially adapted for solid-phase testing
  • G01N33/54386—Analytical elements
  • G01N33/54387—Immunochromatographic test strips
  • G01N33/54388—Immunochromatographic test strips based on lateral flow
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6813—Hybridisation assays
  • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase

Definitions

• the invention pertains to the field of nucleic acid detection. More particularly, the invention pertains to a lateral flow assay for detection of nucleic acid targets.
• Lateral flow immunoassays are a subset of antibody-based immunoassays combining various reagents and process steps in one assay strip, thus providing a sensitive and rapid means for the detection of target molecules. Lateral flow immunoassays are available for a wide area of target analytes and can be designed for sandwich or competitive test principles. Generally high molecular weight analytes with several
• Prior art point-of-care tests such as lateral flow immunochromatography tests, are immunoassays involving an antibody and its antigen. Binding assays in such formats operate on the basis of ligands and receptors and their associated binding constants.
• the inherent deficiencies in the associations between antibodies and their antigens are well known in the art in that ligand-receptor binding assays are prone to degrade with temperature cycling and heat stress while in storage, and interferences often occur from components in the sample matrix, causing non-specific binding during the assay and leading to false results. These inherent limitations do not provide sufficient specificity in the ligand-receptor interaction for reliable assay results.
• Ligand-receptor binding provides the above-mentioned specificity and limitations to a protein antigen target but not to a nucleic acid sequence coding for the protein.
• a binding assay of the present invention includes a target nucleic acid binding in a multiplex structure with at least one sequence in another nucleic acid associated with a label, due to complementary base pairings between at least one sequence in the target nucleic acid with at least one sequence in the labeled nucleic acid.
• the assays of the present invention overcome the inherent deficiencies of antibody-protein antigen assays.
• color tagged nucleic acid sequences are used to bind a complementary target nucleic acid.
• the tagged nucleic acid sequences are preferably made from deoxyribonucleotides, ribonucleotides, or peptide nucleotides.
• Fig. 1 shows a schematic top view of a test strip for a lateral flow binding assay in an embodiment of the present invention.
• Fig. 2 schematically shows a positively-detectable complex of a single-stranded target nucleic acid in a first embodiment of the present invention.
• Fig. 3 schematically shows a double-stranded target nucleic acid in a second embodiment of the present invention.
• Fig. 4 schematically shows a first labeled complex including a nucleic acid sequence that is complementary to an X-binding site of the target nucleic acid shown in Fig. 3 in a second embodiment of the present invention.
• Fig. 5 schematically shows a second complex including a nucleic acid sequence that is complementary to a Y-binding site of the target nucleic acid shown in Fig. 3 in a second embodiment of the present invention.
• Fig. 6 schematically shows a third complex in a second embodiment of the present invention.
• Fig. 7 schematically shows the first complex bound to the X-binding site of the target nucleic acid in the second embodiment of the present invention.
• Fig. 8 schematically shows the first complex bound to the X-binding site of the target nucleic acid and the second complex bound to the Y-binding site of the target nucleic acid in the second embodiment of the present invention.
• Fig. 9 schematically shows the complexes and the target nucleic acid which will be bound to and read at the test line in the second embodiment of the present invention.
• a lateral flow nucleic acid detector of the present invention preferably detects nucleic acids in a sample without utilizing the polymerase chain reaction as an
• the detected nucleic acids are also quantified. Some examples of how the nucleic acids may be quantified include, but are not limited to, quantification through visual gradations of the line intensity or through the use of an electronic optical reader.
• the assays described herein are preferably "point-of-care assays", which, as defined herein, include both lateral flow assays and flow through assays. These point-of- care assays may be run and read within a matter of minutes to a few hours after the sample is obtained, but the assays may alternatively be run at a later time such as up to 24 to 46 hours after obtaining the sample.
• the detector may be used to detect a target nucleic acid sequence associated with any target virus, bacterium, fungus, protozoa, other pathogens, allergens, any genetic deficiency, or any other target nucleic acid in a sample.
• target nucleic acids include, but are not limited to, those that code for tumor markers (oncogenes), cardiac markers (for example, myoglobin, troponin, creatine kinase, MMP-9, C-reactive protein) inflammatory markers (such as cytokines, lymphokines, chemokines, cellular signaling factors, chemo- attractants, metalloproteinases, interferons, MxA, and growth factors), hormones, and tissue typing.
• tumor markers oncogenes
• cardiac markers for example, myoglobin, troponin, creatine kinase, MMP-9, C-reactive protein
• inflammatory markers such as cytokines, lymphokines, chemokines, cellular signaling factors,
• the target nucleic acid may be any nucleic acid including, but not limited to, DNA, an oligonucleotide, messenger RNA, or any other type of RNA.
• the flow of the transport liquid in the detector may be gravity-dependent or as a result of capillary action or surface tension.
• the transport liquid may be applied by dipping the test strip in the transport liquid or the transport liquid may be contained in a test housing for the test strip.
• the nucleic acid sequences used to detect the target nucleic acid sequences can be of any length such that they are specific to the target of interest. In preferred embodiments, the sequences are approximately 10 to 25 nucleotides long, however, longer or shorter sequences are possible, as long as they provide the requisite specificity and do not otherwise interfere with the assay. In some preferred embodiments, the sequences are around 15 to 17 nucleotides long. If peptide nucleic acid sequences (PNAs) are being used, the length may be as short as 10 or 11 nucleotides. IfPCT primers are being used, they are generally 16 to 24 nucleotides long.
• PNAs peptide nucleic acid sequences
• a lateral flow nucleic acid detector of the present invention may be uniplanar with a single sheet on a test strip for the detection zone.
• the detector may be multiplanar with multiple detection zones on multiple sheets in fluid communication for simultaneous assays for the same or different target nucleic acids from the same or different samples.
• a sample for testing in the present invention may be any sample expected to potentially include a target nucleic acid including, but not limited to, saliva, nasopharyngeal secretions, mucus, tissue, blood, urine, tears, vaginal fluid, skin ulcerations, an environmental water sample, and a soil sample.
• a target nucleic acid including, but not limited to, saliva, nasopharyngeal secretions, mucus, tissue, blood, urine, tears, vaginal fluid, skin ulcerations, an environmental water sample, and a soil sample.
• a denaturant or lysis agent in situ to the sample in order to make the nucleic acids in the sample accessible to the first and second complexes.
• the denaturant or lysis agent may be added to the sample prior to application of the sample to the test strip
• the denaturant or lysis agent is preferably pre-loaded onto a zone of the test strip as a dried denaturant or lysis agent so that the sample may be applied directly to the test strip without a step of adding denaturant or lysis agent.
• the lysis agent may be pre-dried by freeze drying or lyophilizing and then pre-loaded into the test strip.
• the lysis agent can be absorbed, adsorbed, embedded, or trapped on the test strip.
• the dried or embedded denaturant or lysis agent is pre-loaded onto the test strip in a location so that it frees the nucleic acids prior to the sample reaching the first complex on the test strip.
• the dried or embedded denaturant or lysis agent is preferably soluble in the transport liquid and located in the sample application zone or between the sample application zone and the zone where the first complex is pre-loaded.
• mild lysis agents may be part of the running buffer. In this scenario, there is no adverse effect on the conjugate zone (the first complex application zone) which will be downstream and the sample may either be upstream or downstream to the conjugate zone.
• the sample traveling with the transport liquid will encounter a lysis agent.
• the lysis agent will have preferably been pre-loaded and dried onto the test strip and is eluted by the transport liquid.
• the initially dried lysis agent is preferably localized between the sample
• the lysis agent is preferably soluble in the sample transport liquid, and the lysis agent is solubilized and activated upon contact with the sample transport liquid.
• the sample transport liquid then contains both lysis agent in solution or suspension and sample components in suspension. Any lysis-susceptible components in a sample, then being exposed in suspension to the lysis agent, are themselves lysed in situ.
• the running buffer then carries the analyte, including any lysis-freed components, to a detection zone.
• the location where the lysis agent is pre-loaded and dried (or embedded) can be varied as needed.
• the lysis agent may be located in or just downstream of the sample application zone.
• the lysis agent may be located closer to the conjugate zone (the first complex application zone).
• the sensitivity of visually read nucleic acid assay tests is enhanced by adding a small quantity of fluorescing dye or fluorescing latex bead conjugates to the initial conjugate material.
• fluorescing dye or fluorescing latex bead conjugates When the visible spectrum test line is visibly present, the test result is observed and recorded.
• a light of an appropriate spectrum such as a UV spectrum, is cast on the test line to excite and fluorescent the fluorescing latex beads which are bound in the test line to enhance the visible color at the test line.
• U.S. Published Patent Application No. 2005/0175992 discloses a method for detecting targets, such as pathogens and/or allergy-associated components, in a human body fluid where the body fluid sample is collected by a collection device, such as a swab member. The samples are transferred from the swab member to a sample analysis device, on which an analysis of the targets can occur by immunochemical or enzymatic means. The test result is capable of being displayed within a very short period of time and can be directly read by the user. This enables point-of-care testing with results available during a patient visit.
• the inventions disclosed in this copending application are particularly advantageous for the diagnosis of conjunctivitis.
• Fig. 1 shows a schematic top view of a test strip for a lateral flow binding assay for nucleic acid detection in an embodiment of the present invention. While the test strip shown in Fig. 1 has a certain configuration, other configurations with different locations for sample application, first and second complex loading, and placement of the denaturant/lysis agent are within the spirit of the present invention.
• the test strip 10 in this example includes a first section 12, a second section 14, a third section 16, and optionally a fourth section 18. These sections are preferably mounted on a backing material 20. Flow occurs in the upward direction 22 of Fig. 1.
• the fourth section 18 serves as an optional waste pad for collecting the transport liquid and materials flowing past the third section 16, also termed the detection zone herein, which preferably includes a nitrocellulose membrane.
• a first complex is loaded onto a conjugate zone, which is the lower portion 24 of the second section 14 in this figure.
• a second complex as described below, is loaded onto a test zone 26 of the detection zone 16.
• the second complex is loaded onto the upper portion 30 of the second section 14.
• the second complex includes an immobilization agent, such as biotin, and the test zone 26 has an immobilization site, such as an avidin, neutrAvidin, or streptavidin functionality for binding the second complex to the test zone 26.
• a third complex is preferably loaded onto a control zone 28 of the detection zone 16 above the test zone 26.
• ⁇ 00132817.DOC ! ⁇ 28 are preferably zones with lengths much greater than their widths on the detection zone 16.
• the target nucleic acid in the sample to be tested moves faster than the first complex in the transport liquid.
• the sample is loaded onto the first section 12 below the first complex and a transport liquid, such as a running buffer, is applied to the first section 12 below where the sample is loaded to perform the assay.
• the sample solution itself may be used as the transport liquid in this embodiment.
• the target nucleic acid in the sample to be tested moves slower than the first complex in the transport liquid.
• the sample is loaded onto the upper portion 30 of the second section 14 and the transport liquid is applied to the first section 12 of the test strip.
• the assay is preferably run until substantially all the first complex which has not bound to the test line 26 reaches the control line 28.
• the location of sample loading and first complex loading depends on the conditions of the assay, and may be varied as long as the sample encounters the first complex on the test strip such that the target nucleic acid sequence can bind to the complementary nucleic acid sequence on the labeled first complex.
• the sample may be added directly onto the first complex (the conjugate) and other embedded materials or slightly downstream or slightly upstream from the first complex and the embedded materials.
• At least one first nucleic acid sequence is conjugated to a label to form the first complex.
• label refers to any atom, atoms, molecule, or molecules, such as a fluorescent tag, attached to or associated with a nucleic acid and used to provide a detectable and preferably quantifiable signal.
• the nucleic acid sequence may be suitably associated with the label through a non- covalent association such as biotin-avidin.
• the label may be microbeads such as colloidal gold particles mixed with fluorescence or fluorescent beads, or dyed latex beads, where the dye may be a visual dye such as a red dye, a fluorescent dye, a phosphorescent dye, or a chemiluminescent dye.
• the dye may be a visual dye such as a red dye, a fluorescent dye, a phosphorescent dye, or a chemiluminescent dye.
• Methods of detection of the label include, but are not limited to, fluorescence, chemoluminescence, radioactivity, colorimetry, gravimetry, X-ray diffraction, X-ray absorption, magnetism, and enzymatic activity. Visible spectrum test
• the first complex is placed on the lateral flow strip in a form such that the first complex is mobilized by a transport liquid such as a running buffer or by a sample applied to the lateral flow strip.
• Qualitative interpretation is performed visually by observing the test line intensity and hue.
• a visual red dye used as the label
• the test line can be seen faintly and the hue is pink.
• the concentration of the analyte is increased, the test line intensity correspondingly increases and the hue shifts from pink to bright red.
• a quantitative interpretation is developed using a spectrometer operating in the visible spectrum. Either an absorption or a reflectance measurement may be used in the visible spectrum to develop the quantification of the test line. First a set of characterized concentrations of the analyte are developed. Each of the concentrations are applied to the sample application zone and the test is developed.
• the spectrometer is used to measure either the absorbtion or the reflectance of the test line.
• a standard curve is calculated from the measured values of the spectrometer.
• the standard curve is normally linear.
• fluorescent tags if fluorescent tags are used, a similar set of known concentrations of the analyte may be developed.
• An unknown concentration of the analyte tested and quantified by the spectrometer yields a value that, when plotted on the standard curve, can be correlated to a concentration of analyte.
• a second nucleic acid sequence is immobilized in a second complex on the lateral flow test strip in the test zone.
• the second nucleic acid sequence may be immobilized by a variety of ways to form the second complex within the spirit of the present invention.
• the immobilization may be direct, where the immobilization is achieved by binding the nucleic acid sequence to at least one chemical, or indirect, where the immobilization is achieved by physically trapping the nucleic acid sequence with at least one chemical or other moiety.
• Immobilization methods include, but are not limited to, associating with poly-lysine, coupling to microbeads, and incorporating into a hydrogel.
• microbeads such as latex beads
• a medium such as a nitrocellulose membrane, a nylon, or a polyester.
• the hydrogel may be immobilized in a suitable medium directly or by a trapping mechanism.
• a single continuous sequence of the target nucleic acid could be complementary to both the first nucleic acid sequence and the second nucleic acid sequence.
• a peptide nucleic acid sequence (PNAs) of 25 nucleotides is complementary to a portion of a target nucleic acid. Approximately half of those nucleotides (e.g. eleven or twelve nucleotides) are used as the first nucleic acid sequence in the first complex and the other half of the nucleotides (e.g. twelve or thirteen nucleotides) are used as the second nucleotide acid sequence in the second complex.
• the first nucleic acid sequence binds to one portion of the single sequence of the target nucleic acid and the second nucleic acid sequence binds to a second portion of the single sequence of the target nucleic acid.
• the second nucleic acid sequence is associated with an immobilization agent to form a second complex.
• the second complex is loaded onto the upper portion 30 of the second section 14 of the test strip.
• a receptor for the immobilization agent is immobilized at an immobilization site on the test zone 26. When the immobilization agent reaches the test zone during the assay, it binds to the receptor to immobilize the second complex on the test zone 26.
• the immobilization agent and the receptor may be any pair with a strong specific interaction which does not interfere with the desired nucleic acid interactions of the assay.
• the immobilization agent may be biotin and the receptor may be avidin, neutrAvidin, or streptavidin.
• the immobilization agent may be a lectin and the immobilization site may be a glycosyl moiety.
• the lectin is the Garden pea Lectin and the glycosyl moiety is an erythrocyte glycosyl unit.
• the immobilization agent and the immobilization site may be reversed within the spirit of the present invention.
• avidin may be complexed with the second nucleic acid sequence to form the second complex, with biotin acting as the receptor at the immobilization site at the test zone 26.
• a third nucleic acid sequence complementary to the first nucleic acid sequence is immobilized in a third complex on the control zone.
• the third nucleic acid may be immobilized by any of the variety of ways discussed above with respect to the second nucleic acid sequence within the spirit of the present invention.
• the third complex is designed such that in the running of an assay, any
• any of the first complex not bound to the target nucleic acid is detected, and in some embodiments, quantified.
• an assay of the present invention may be run without a control zone, a control zone is preferred for confirming negative test results and for comparison to the test zone for positive test results.
• the target nucleic acid may be any nucleic acid sequence including, but not limited to, a nucleic acid sequence from a virus, a bacterium, a fungus, a plant, an animal, an artificially produced sequence, a genetically modified organism (GMO), or a fossilized specimen.
• the sample is applied to the strip in a sample application zone.
• the sample application zone may precede the first complex, overlap the first complex, or follow the first complex on the test strip.
• a transport liquid is used to mobilize the first complex and transport the first complex to expose it to any of the target nucleic acid the sample.
• the test zone is composed of at least one immobilized nucleic acid sequence that is a sequence used in traditional polymerase chain reaction (PCR) assays.
• the sequence is preferably made from deoxyribonucleotides, ribonucleotides, or peptide nucleotides.
• the first complex includes such a PCR-type primer of the target nucleic acid conjugated to a label.
• primers are preferably the anti-sense nucleotide sequences that complement their corresponding "sense" sequences of nucleic acid from organisms such as viruses, bacteria, and fungi.
• the sense and anti-sense primers may be interchanged in the lateral flow assay within the spirit of the present invention.
• test lines are within the spirit of the invention.
• the presence of each target preferably corresponds to a separate test line.
• the presence of multiple targets may be indicated on the same test line such that the presence of more than one target has different characteristics than the presence of a single target. For example, the presence of multiple
• targets on the same test line may be visually indicated by a different color than the presence of each of the targets alone.
• Fig. 2 shows a positively-detectable complex of a target nucleic acid in a first embodiment of the present invention.
• the target nucleic acid 40 in the sample is a single-stranded nucleic acid sequence.
• the first complex 42 includes at least one first nucleic acid sequence 44 complementary to an inner part of the sequence of the target nucleic acid 40.
• the first nucleic acid sequence 44 is associated with a label 46.
• the second complex includes at least one second nucleic acid sequence 48 complementary to an outer part of the sequence of the target nucleic acid 40.
• the first nucleic acid sequence 44 is preferably an inner PCR primer and the second nucleic acid sequence 48 is preferably an outer PCR primer.
• the first nucleic acid sequence 44 is an outer PCT primer and the second nucleic acid sequence 48 is an inner PCR primer.
• one first nucleic acid sequence and one label is sufficient for each first complex, a first complex preferably has multiple copies of the first nucleic acid sequence, as shown in Fig. 2, and multiple label units, shown as asterisks in Fig. 2. Although eight nucleic acid sequences are shown in Fig. 2, any number which promotes binding of the first complex to the target nucleic acid may be used within the spirit of the present invention.
• Figs. 3 through 9 show a positively-detectable complex of a target nucleic acid in a second embodiment of the present invention.
• the target nucleic acid 50 in the sample is a double-stranded nucleic acid.
• the target nucleic acid 50 in the sample is preferably denatured in situ, preferably by a denaturant or lysis agent such as DNAzole Direct, formamide, or urea, to open up at least a portion of the double strand to a first strand 52 and a second strand 54.
• a denaturant or lysis agent such as DNAzole Direct, formamide, or urea
• denaturing of the nucleic acid may be achieved by adjusting or controlling the tonicity, the temperature, or the pH of the assay within the
• a partial opening is preferred for detection in the lateral flow assay, although an assay of the present invention may be run with either partial or complete denaturing of the nucleic acid in the sample.
• the denaturant or lysis agent is located in the sample application zone such that the nucleic acid is denatured and/or lysed soon after it is added to the test strip.
• the denaturant or lysis agent is placed on any location on the test strip such that the target nucleic acid is at least partially denatured and/or lysed prior to or while encountering the first labeled complex 56.
• the first complex 56 includes at least one first nucleic acid sequence 58, which is preferably a primer or oligonucleotide anti-sense sequence 58 to the first strand 52 of the target nucleic acid sequence.
• the first nucleic acid sequence 58 is associated with a label 60.
• the label may be any atom, atoms, molecule, or molecules, such as a visual or fluorescent tag, attached to or associated with a nucleic acid and used to provide a detectable and preferably quantifiable signal.
• the nucleic acid sequence may be suitably associated with the label through a non-covalent association such as biotin-avidin.
• the label may be microbeads such as colloidal gold particles mixed with fluorescence or fluorescent beads, or dyed latex beads, where the dye may be a visual dye such as a red dye, a fluorescent dye, a phosphorescent dye, or a chemiluminescent dye.
• Fig. 5 shows the second complex 62, which includes at least one second nucleic acid sequence 64, which is preferably an anti-sense primer or oligonucleotide, and an immobilization agent 66, such as biotin.
• the second nucleic acid sequence 64 is complementary to a Y-binding site of the second strand 54 of the target nucleic acid 50.
• the second complex 62 is preferably located on the upper portion 30 of the second section 14 of the test strip 10 shown in Fig. 1, and a receptor, such as an avidin-linked probe 70 shown in Fig. 6, is immobilized on the test zone 26 (preferably a nitrocellulose membrane) of the test strip 10 at the start of the assay.
• the second complex could alternatively be impregnated on the portion of the test strip upon which the sample is loaded or in any location in which it will encounter the sample before the sample reaches the detection zone.
• the second complex does not necessarily need to be located downstream of the first complex.
• a sample pad may be impregnated with
• avidin 72 and biotin 66 are shown as the immobilization agents in these figures, other immobilization agents as discussed herein or otherwise known in the art could alternatively be used.
• the first complex 56 when the lateral flow is initiated by dipping the absorbent tip in the transport liquid, the first complex 56 is mobilized, and the primer or the oligonucleotide sequence 58 on the first complex 56 complexes with the first strand 52 of the opened nucleic acid at an X-binding site, as shown in Fig. 7.
• the first complex 56 and the sample nucleic acid 50 may be located anywhere on the test strip such that they encounter each other while being eluted through the test strip.
• the first-complex-target-nucleic-acid is then exposed to the second complex 62.
• the second sequence 64 complexes with the second strand 54 at a Y-binding site as shown in Fig. 8.
• the entire complex shown in Fig. 8 then moves to the test zone, where the biotin 66 is captured by avidin 72 immobilized in the test zone through the binding of the biotin 66 to the avidin 72. This produces a visibly read line.
• the test zone becomes visible only when the target nucleic acid sequence is present in the sample, indicating that the sample is positive for the target nucleic acid. In a negative sample, where the target nucleic acid sequence is absent, the test zone remains colorless.
• the intensity of the test zone may be augmented by fluorescence either associated with the visually tagged conjugate particles or mixed with fluorescent conjugate particles.
• the X-binding site and Y-binding site are preferably non-overlapping sequences, since the first and second nucleic acid sequences are preferably both complementary anti-sense sequences of the target nucleic acid.
• the quality of the engineered primers is important to prevent any potential direct binding between the first sequence and the second sequence in the absence of the target nucleic acid, which would give a false positive test result.
• the lateral flow assay tests for more than one target nucleic acid in a sample.
• a separate set of first complexes and second complexes are used for each target nucleic acid to be detected.
• each first complex has a different label detectable by a different method
• each target nucleic acid may be separately detected and quantified without interference from the other target nucleic acids.
• test result is obtained in under 10 minutes after applying the sample to the device, and it is preferably read at approximately 10 minutes. In samples that are highly positive, a readout of the test zone (preferably a test line) is visible within 1 to 5 minutes.

Landscapes

• Health & Medical Sciences (AREA)
• Immunology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Molecular Biology (AREA)
• Biomedical Technology (AREA)
• Hematology (AREA)
• Urology & Nephrology (AREA)
• Biochemistry (AREA)
• Biotechnology (AREA)
• Organic Chemistry (AREA)
• Microbiology (AREA)
• General Health & Medical Sciences (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Zoology (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Food Science & Technology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Cell Biology (AREA)
• Wood Science & Technology (AREA)
• Biophysics (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Engineering & Computer Science (AREA)
• Genetics & Genomics (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Peptides Or Proteins (AREA)
• Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
• Investigating Or Analysing Biological Materials (AREA)

Priority Applications (2)

Applications Claiming Priority (10)

Publications (2)

Family

ID=41550997

Family Applications (2)

Family Applications After (1)

Country Status (3)

Cited By (3)

Families Citing this family (10)

Family Cites Families (19)

• 2009
  • 2009-07-15 JP JP2011518872A patent/JP2012503170A/ja active Pending
  • 2009-07-15 JP JP2011518870A patent/JP5948056B2/ja not_active Expired - Fee Related
  • 2009-07-15 EP EP09798690A patent/EP2313527A4/en not_active Ceased
  • 2009-07-15 EP EP09798691A patent/EP2313775A4/en not_active Withdrawn
  • 2009-07-15 WO PCT/US2009/050645 patent/WO2010009203A2/en not_active Ceased
  • 2009-07-15 WO PCT/US2009/050653 patent/WO2010009206A2/en not_active Ceased

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events